Improved treatment of migraine headache

Abstract From the Canadian patent

This invention comprises a non-vasoactive supra-vasoactive syndrome ("SVS") , minimized dosage form for treatment of migraine in a human comprising (i) rapid availability metoclopramide in at least about an effective local gastrointestinal amount; (ii) at least one long acting NSAID such as naproxen sodium in a therapeutically effective amount; (iii) wherein said dosage form is a coordinated dosage form; and, (iv) wherein the dosage form is absent 5HT agonist vasoactive agents and , preparation thereof. Acid-base stable dosage forms are noted. This invention further comprises methods of migraine treatment and , methods for rapid introduction of oral NSAID into the small bowel.